💰 The Income Generators (High Probability, Cash Flow)
DDOG: Bullish Put Spread capitalizing on a major technical breakout supported by the end of cloud optimization headwinds and surging AI observability demand.
🚀 The Growth Seekers (Higher Risk, Max Reward)
NVO: Bullish Call Spread targeting a breakout extension driven by expanding GLP-1 supply capacity and positive pipeline data.
🛡️ The Portfolio Protectors (Hedges & Bearish Bets)
PFE: Bearish Put Spread hedging against severe relative weakness, pipeline stagnation, and balance sheet constraints following recent acquisitions.
1. DDOG ($140.53) – The Bottoming Breakout
We’re betting on: If Datadog sustains its momentum after a prolonged consolidation phase, the stock will push toward its $165 target and stay safely above our $140 strike through mid-June.
The Trade: Sell to Open the DDOG Jun 18, 2026 140/125 Put Vertical @ $6.42 Credit.
🟢 BUY TO OPEN Jun 18, 2026 125 Put @ $6.88
🔴 SELL TO OPEN Jun 18, 2026 140 Put @ $13.30
Trade Metrics: POP: 52.64% | Collect $642.00 per contract vs. a Max Risk of $858.00 (1.3:1).
The Setup: Datadog broke out above $135 after a prolonged 2026 bottoming phase, opening the door toward a $165 target. Fundamentally, “cloud optimization” headwinds have cleared. As enterprise IT budgets aggressively pivot toward AI observability and vendor consolidation, DDOG’s unified platform is perfectly positioned to capture spend. With cloud consumption reaccelerating, this put spread captures premium against a newly established structural floor.
Management:
⚠️ Warning: Earnings is scheduled for May 07, which requires active management.
Stop Loss: Buy back the spread at $12.84 (100% of credit received).
Take Profit: Buy back the spread at $3.21 (50% of max gain).
2. NVO ($43.88) – Pushing Past Resistance
We’re betting on: If Novo Nordisk accelerates through its breakout on the back of easing supply bottlenecks and robust prescription demand, the stock will surge into our target profit zone.
The Trade: Buy to Open the NVO Jun 18, 2026 40/50 Call Vertical @ $4.24 Debit.
🟢 BUY TO OPEN Jun 18, 2026 40 Call @ $5.30
🔴 SELL TO OPEN Jun 18, 2026 50 Call @ $1.06
Trade Metrics: POP: 44.61% | Pay $424.00 per contract vs. a Max Reward of $576.00 (1.4:1).
The Setup: NVO is breaking out from a recent bottoming formation near $40 resistance, targeting a move to $49. Fundamentally, a massive inflection in manufacturing capacity is easing revenue bottlenecks for its GLP-1 portfolio. Combined with strong clinical data for its next-generation oral obesity pipeline, institutional buying has reignited. This long call spread offers an excellent risk-to-reward ratio to capture the breakout.
Management:
⚠️ Warning: Earnings is scheduled for May 06, which requires active management.
Stop Loss: Sell the spread at $2.12 (50% loss on premium).
Take Profit: Sell the spread at $7.42 (75% gain on premium).
3. PFE ($26.33) – Fading the Weakness
We’re betting on: If Pfizer continues to bleed relative strength amid pipeline stagnation and margin compression, it will fail to hold structural support and flush lower towards $24.50.
The Trade: Buy to Open the PFE Jun 18, 2026 27/25 Put Vertical @ $0.97 Debit.
🔴 SELL TO OPEN Jun 18, 2026 25 Put @ $0.49
🟢 BUY TO OPEN Jun 18, 2026 27 Put @ $1.46
Trade Metrics: POP: 45.55% | Pay $97.00 per contract vs. a Max Reward of $103.00 (1.1:1).
The Setup: Pfizer has tested $26 support for three months, and its poor relative strength signals a high-probability breakdown toward $24.50. Fundamentally, the company is struggling to replace its post-COVID revenue cliff. A heavily leveraged balance sheet from the Seagen acquisition severely limits buybacks and M&A, while recent clinical updates lag competitors in the obesity space. This put spread capitalizes on the lack of near-term growth catalysts.
Management:
⚠️ Warning: Earnings is scheduled for May 05, which requires active management.
Stop Loss: Sell the spread at $0.48 (50% loss on premium).
Take Profit: Sell the spread at $1.70 (75% gain on premium).
Share this on